What about this??? Beverly, MA — 06/26/13
Post# of 72436
Beverly, MA — 06/26/13 — Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the Company has signed a Material Transfer Agreement (MTA) with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”). Per the MTA, Cellceutix will provide MD Anderson with Kevetrin, the Company’s novel anti-cancer drug candidate, for laboratory research of Kevetrin as a potential new treatment for Lymphoma and Multiple Myeloma.
- See more at: http://cellceutix.com/cellceutix-signs-materi...AQji2.dpuf
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)